MX2011011618A - Agentes terapeuticos 713. - Google Patents

Agentes terapeuticos 713.

Info

Publication number
MX2011011618A
MX2011011618A MX2011011618A MX2011011618A MX2011011618A MX 2011011618 A MX2011011618 A MX 2011011618A MX 2011011618 A MX2011011618 A MX 2011011618A MX 2011011618 A MX2011011618 A MX 2011011618A MX 2011011618 A MX2011011618 A MX 2011011618A
Authority
MX
Mexico
Prior art keywords
therapeutic agents
melanin
prophylaxis
compounds
formula
Prior art date
Application number
MX2011011618A
Other languages
English (en)
Inventor
Lars Anders Mikael Johansson
Robert Andrew Judkins
Lanna Li
Bjorn Christian Ingvar Lofberg
Joachim Persson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2011011618A publication Critical patent/MX2011011618A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente, se describen compuestos de fórmula I (ver fórmula (II)) en donde R1, R2, R3, R4, R5, A, X, Y son como se han descrito en la especificación, su uso en composiciones farmacéuticas y en métodos de tratamiento o profilaxis de una enfermedad o afección relacionada con la hormona concentradora de melanina.
MX2011011618A 2009-05-01 2010-04-29 Agentes terapeuticos 713. MX2011011618A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17463009P 2009-05-01 2009-05-01
PCT/GB2010/050698 WO2010125390A1 (en) 2009-05-01 2010-04-29 Therapeutic agents 713

Publications (1)

Publication Number Publication Date
MX2011011618A true MX2011011618A (es) 2011-11-18

Family

ID=42290768

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011618A MX2011011618A (es) 2009-05-01 2010-04-29 Agentes terapeuticos 713.

Country Status (23)

Country Link
US (1) US8110566B2 (es)
EP (1) EP2424870B1 (es)
JP (1) JP5763052B2 (es)
KR (1) KR20120023044A (es)
CN (2) CN102459279B (es)
AR (1) AR076516A1 (es)
AU (1) AU2010243341B2 (es)
BR (1) BRPI1014387A2 (es)
CA (1) CA2759230A1 (es)
DK (1) DK2424870T3 (es)
ES (1) ES2562831T3 (es)
HR (1) HRP20160128T1 (es)
HU (1) HUE026856T2 (es)
MX (1) MX2011011618A (es)
PL (1) PL2424870T3 (es)
PT (1) PT2424870E (es)
RU (1) RU2526055C2 (es)
SA (1) SA110310332B1 (es)
SI (1) SI2424870T1 (es)
SM (1) SMT201600041B (es)
TW (1) TW201100433A (es)
UY (1) UY32593A (es)
WO (1) WO2010125390A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010507619A (ja) * 2006-10-25 2010-03-11 ノイロサーチ アクティーゼルスカブ オキサジアゾール及びチアジアゾール化合物並びにニコチン性アセチルコリン受容体調節物質としてのその使用
EA201291384A1 (ru) * 2010-07-06 2013-07-30 Астразенека Аб Терапевтические агенты 976
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
HU230880B1 (hu) 2015-04-15 2018-11-29 Richter Gedeon Nyrt Indol származékok
WO2021142395A1 (en) * 2020-01-10 2021-07-15 Consynance Therapeutics, Inc. Therapeutic combinations of drugs and methods of using them
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2292931T3 (es) * 2002-02-01 2008-03-16 Novo Nordisk A/S Amidas de azetidinas, pirrolidinas, piperidinas y azepanos aminoalquilo sustituidos.
SE0202134D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
AU2003252715B2 (en) 2002-07-30 2009-06-04 Banyu Pharmaceutical Co., Ltd. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
US7601868B2 (en) 2003-02-12 2009-10-13 Takeda Pharmaceutical Company Limited Amine derivative
US20060293298A1 (en) * 2003-04-10 2006-12-28 Bamford Mark J Compounds
GB0400193D0 (en) 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
WO2005066132A1 (en) 2004-01-07 2005-07-21 Astrazeneca Ab Therapeutic agents i
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
TW200538098A (en) 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
BRPI0513777A (pt) * 2004-07-26 2008-05-13 Lilly Co Eli composto ou um sal do mesmo, composição farmacêutica, e, uso de um composto ou de um sal do mesmo
EP1805169B1 (en) 2004-10-18 2008-12-24 Eli Lilly And Company Histamine h3 receptor inhibitors, their preparation and therapeutic uses
EP1828177B1 (en) 2004-12-17 2008-08-13 Eli Lilly And Company Novel mch receptor antagonists
EP1831194A4 (en) 2004-12-21 2009-12-02 Astrazeneca Ab HETEROCYCLIC ANTAGONISTS OF MCHr1 AND THERAPEUTIC APPLICATIONS THEREOF
JP2006176443A (ja) 2004-12-22 2006-07-06 Shionogi & Co Ltd メラニン凝集ホルモン受容体アンタゴニスト
WO2006130075A1 (en) 2005-05-31 2006-12-07 Astrazeneca Ab Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders
WO2007011284A1 (en) 2005-07-15 2007-01-25 Astrazeneca Ab Therapeutic agents
CN101400677A (zh) 2006-01-06 2009-04-01 阿斯利康(瑞典)有限公司 化合物
WO2008011453A2 (en) 2006-07-20 2008-01-24 Amgen Inc. SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1
EP2121703A4 (en) 2006-08-18 2011-12-28 Astrazeneca Ab THIENOPYRIMIDIN-4-ON- AND THIENOPYRIDAZIN-7-ONDERIVATES AS MCH-RL ANTAGONISTS
WO2008068265A1 (en) 2006-12-05 2008-06-12 Janssen Pharmaceutica N.V. Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases
BRPI0721086A2 (pt) 2006-12-14 2014-02-25 Lilly Co Eli Derivados de 5-[4-(azetidin-3-ilóxi)-fenil]-2-fenil-5h-tiazolo[5,4-c]piri din-4-ona e seu emprego como antago-nistas de receptor de mch
JP2010524962A (ja) 2007-04-17 2010-07-22 バーテックス ファーマシューティカルズ インコーポレイテッド オーロラキナーゼ阻害剤のための創薬法
WO2009024502A1 (en) 2007-08-22 2009-02-26 F. Hoffmann-La Roche Ag Pyrrolidine aryl-ether as nk3 receptor antagonists
CA2702467C (en) * 2007-10-17 2012-11-27 Sanofi-Aventis Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
AU2009261248A1 (en) * 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative

Also Published As

Publication number Publication date
HUE026856T2 (en) 2016-07-28
CN102459279B (zh) 2014-06-25
DK2424870T3 (en) 2016-02-15
AU2010243341B2 (en) 2014-02-13
EP2424870B1 (en) 2015-12-16
CN103936751A (zh) 2014-07-23
UY32593A (es) 2010-11-30
HRP20160128T1 (hr) 2016-02-26
WO2010125390A1 (en) 2010-11-04
SI2424870T1 (sl) 2016-03-31
JP5763052B2 (ja) 2015-08-12
BRPI1014387A2 (pt) 2017-06-06
AU2010243341A1 (en) 2011-11-03
RU2526055C2 (ru) 2014-08-20
EP2424870A1 (en) 2012-03-07
PL2424870T3 (pl) 2016-05-31
PT2424870E (pt) 2016-03-17
US20100280000A1 (en) 2010-11-04
US8110566B2 (en) 2012-02-07
SA110310332B1 (ar) 2013-12-10
ES2562831T3 (es) 2016-03-08
JP2012525365A (ja) 2012-10-22
CN102459279A (zh) 2012-05-16
SMT201600041B (it) 2016-02-25
CA2759230A1 (en) 2010-11-04
KR20120023044A (ko) 2012-03-12
TW201100433A (en) 2011-01-01
AR076516A1 (es) 2011-06-15

Similar Documents

Publication Publication Date Title
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
IN2012DN01233A (es)
MX337575B (es) Compuestos de sulfona y métodos para lafabricación y uso de éstos.
MX2012004525A (es) Compuestos.
TW200738242A (en) Dihydropteridinones in the treatment of respiratory diseases
MX2012007273A (es) Pteridinonas como inhibidores de la quinasa tipo polo.
UA115558C2 (uk) Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань
GEP20146125B (en) Aminopyrimidines as syk inhibitors
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
EP2400847A4 (en) SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
TN2011000172A1 (en) Therapeutic antiviral peptides
IN2012DN00971A (es)
IN2012DN00869A (es)
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
MY150931A (en) Substituted oxazolidinones and their use
MX2011011618A (es) Agentes terapeuticos 713.

Legal Events

Date Code Title Description
FG Grant or registration